Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines

Canadian Journal of Gastroenterology

Volumn 26, Issue 12, 2012, Pages 917-938

  Coffin, Carla S ^a   Fung, Scott K ^b   Ma, Mang M ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiviral therapy; Canadian; Chronic hepatitis B; Hepatitis B virus infection; Management

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL THERAPY; ARTICLE; CANADA; CHRONIC DISEASE; CHRONIC HEPATITIS B; CLINICAL PRACTICE; CONSENSUS; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIAGNOSTIC TEST; DRUG FEVER; DRUG SAFETY; ELASTOGRAPHY; FLU LIKE SYNDROME; GENE MUTATION; GENOTYPE; HEADACHE; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATOMA CELL; HIGH RISK PATIENT; HOST; HUMAN; HYPOPHOSPHATEMIA; IMMUNE DEFICIENCY; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LOCAL INJECTION SITE REACTION; MALAISE; MEDICAL LITERATURE; MOOD CHANGE; MYALGIA; NEPHROTOXICITY; PATIENT ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING TEST; SIDE EFFECT; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; VIROLOGY; VULNERABLE POPULATION;

EID: 84871062776     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/506819     Document Type: Article

References (263)

1. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: Consensus guidelines. Can J Gastroenterol 2007;21(Suppl C):5C-24C. (Pubitemid 47162250)
2. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003;139:493-8. (Pubitemid 38124575)
3. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-51.
4. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-3. (Pubitemid 351809277)
5. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-8. (Pubitemid 351656090)
6. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
7. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744.
8. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-10. (Pubitemid 351731739)
9. Organization WH. Hepatitis B (Fact sheet no. 204). Geneva, Switzerland: World Health Organization, 2008.
10. Wu HX, Andonov A, Giulivi A, et al. Enhanced surveillance for childhood hepatitis B virus infection in Canada, 1999-2003. Int J Med Sci. 2005;2:143-6. (Pubitemid 41382987)
11. Decision Analysis on Screening for HBV in Immigrants. Statistics and Risk Assessment Section of the Blood Safety Surveillance and Health CareAcquired Infection Division, Population and Public Health Branch Health Canada, 2000.
12. Minuk GY, Uhanova J. Chronic hepatitis B infection in Canada. Can J Infect Dis 2011;12:351-6.
13. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94. (Pubitemid 38032767)
14. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381-96.
15. Kwong JC, Crowcroft NS, Campitelli MA, Ratnasingham S, Daneman N, Deeks SL, Manuel DG. Ontario Burden of Infectious Disease Study Advisory Group; Ontario Burden of Infectious Disease Study (ONBOIDS): An OAHPP/ICES Report. Toronto: Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences; 2010.
16. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J 2005;24:755-60. (Pubitemid 41324881)
17. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol 1993;138:544-9. (Pubitemid 23315089)
18. 2007 British Columbia Annual Summary of Reportable Diseases. BC Centre for Disease Control, Monika Naus ed. Vancouver; 2008.
19. Expanded Programme on Immunization of the Department of Immunizations, Vaccines and Biologicals. WHO vaccine-preventable diseases monitoring system, 2007 global summary. Geneva (Switzerland), 2007.
20. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002;325:569.
21. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786-92. (Pubitemid 41324887)
22. Liao SS, Li RC, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: A 15-year follow-up study among Chinese children. Vaccine 1999;17:2661-6. (Pubitemid 29314462)
23. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004;2:941-5. (Pubitemid 39335802)
24. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: The role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-85.
25. Active Immunizing Agents Hepatitis B vaccine, Canadian Immunization guide Seventh Edition - 2006. David Butler-Jones, ed. Ottawa: Public Health Agency of Canada.
26. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33; quiz CE1-4.
27. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000;14(Suppl B):59B-62B.
28. Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2011;60:1709-11.
29. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988;8:766-70.
30. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001;165:1063-4. (Pubitemid 32964871)
31. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. (Pubitemid 27527771)
32. Liaw YF, Chu CM, Huang MJ, Sheen IS, Yang CY, Lin DY. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984;4:301-6.
33. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839-43. (Pubitemid 17072230)
34. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991;13:627-31.
35. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-47.
36. Liaw YF. Hepatitis B virus replication and liver disease progression: The impact of antiviral therapy. Antivir Ther 2006;11:669-79.
37. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72. (Pubitemid 16144862)
38. Lin X, Robinson NJ, Thursz M, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: Review of disease progression. J Gastroenterol Hepatol 2005;20:833-43. (Pubitemid 40897163)
39. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006;43(2 Suppl 1):S173-81.
40. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803. (Pubitemid 44166589)
41. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86. (Pubitemid 43374518)
42. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
43. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005;97:265-72.
44. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71. (Pubitemid 35333911)
45. Del Poggio P, Colombo S. Is transient elastography a useful tool for screening liver disease? World J Gastroenterol 2009;15:1409-14.
46. Zhu X, Wang LC, Chen EQ, et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci 2011;56:2742-9.
47. Coco B, Oliveri F, Maina AM, et al. Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360-9. (Pubitemid 46587854)
48. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47:380-4. (Pubitemid 351280705)
49. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36-44.
50. Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg 2003;96:1392-6. (Pubitemid 36512882)
51. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-73. (Pubitemid 16125908)
52. Huang JF, Hsieh MY, Dai CY, et al. The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut 2007;56:736-7.
53. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003;39:239-44. (Pubitemid 36920560)
54. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: A quantitative reference standard. Hepatology 1998;28:323-31. (Pubitemid 28363655)
55. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol 2010;52:514-22.
56. Sonneveld MJ, Rijckborst V, Boucher CA, et al. A comparison of two assays for quantification of Hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol 2011;51:175-8.
57. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011;50:292-6.
58. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010;52:1232-41.
59. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010;139:483-90.
60. Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011;204:408-14.
61. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50.
62. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
63. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: Genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309. (Pubitemid 39541275)
64. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003;46:329-38. (Pubitemid 38037030)
65. Palumbo E. Hepatitis B genotypes and response to antiviral therapy: A review. Am J Ther 2007;14:306-9. (Pubitemid 46791570)
66. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-107.
67. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9.
68. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365:123-9. (Pubitemid 40091801)
69. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-2.
70. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
71. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005;54:1610-4. (Pubitemid 41531781)
72. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
73. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995;22:1387-92.
74. Yuen M-F, Yuan H-J, Wong DK-H. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005;54:1610-4. (Pubitemid 41531781)
75. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
76. Fung SK, Lok AS. Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? Hepatology 2004;40:790-2. (Pubitemid 39288110)
77. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. (Pubitemid 39265273)
78. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-62. (Pubitemid 34651418)
79. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-56. (Pubitemid 35408309)
80. Brook MG, McDonald JA, Karayiannis P, et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: Factors that influence response. Gut 1989;30:1116-22. (Pubitemid 19202212)
81. Brunetto MR, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol. 2003;39(Suppl 1):S164-7. (Pubitemid 37222666)
82. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39(Suppl 1):S99-105.
83. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301. (Pubitemid 20237094)
84. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23. (Pubitemid 23319890)
85. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71. (Pubitemid 40646544)
86. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. (Pubitemid 41007823)
87. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7. (Pubitemid 26157437)
88. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7. (Pubitemid 27461254)
89. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
90. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-8. (Pubitemid 24002802)
91. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
92. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-97.
93. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:1945-53.
94. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42. (Pubitemid 27509322)
95. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
96. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251-7.
97. Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-42.
98. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17. (Pubitemid 39296307)
99. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-79, e1-4.
100. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
101. Marcellin P, Buti M, Gane E, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011). Hepatology 2011;54(Suppl 4):A1375. (Abst).
102. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-73.
103. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5. (Pubitemid 39657017)
104. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
105. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10. (Pubitemid 43357804)
106. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-507. (Pubitemid 39129351)
107. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65. (Pubitemid 44953670)
108. Chang T, Chao T, Kaymakoglu S, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg positive patients (Abstract 223). 57th Annual Meting of the American Association for the Study of Liver Disease, Boston, October 27 to 31, 2006.
109. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. (Pubitemid 43357805)
110. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108. (Pubitemid 351975535)
111. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22. (Pubitemid 37500436)
112. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96. (Pubitemid 36337972)
113. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol 2010;53:348-56.
114. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
115. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-20.
116. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16. (Pubitemid 36245757)
117. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-9. (Pubitemid 43260045)
118. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88. (Pubitemid 350294224)
119. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95.
120. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215-21.
121. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166:49-56. (Pubitemid 43063841)
122. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. J Hepatol 2005;43:60-6. (Pubitemid 40805273)
123. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101. (Pubitemid 38040727)
124. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36. (Pubitemid 41096641)
125. Lok A, Trinh H, Carosi G. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): The BE-LOW study. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011). Hepatology 2011;54(Suppl 4):223. (Abst).
126. Liaw YF, Sheen IS, Lee CM, A et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
127. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7. (Pubitemid 47127032)
128. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65. (Pubitemid 47171942)
129. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15. (Pubitemid 39307089)
130. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: Evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002;40:3729-34.
131. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-43. (Pubitemid 41627977)
132. Dienstag JL, Wei LJ, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:35-49. (Pubitemid 46058733)
133. Lai C, Leung N, Teo E. One-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528.
134. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-91. (Pubitemid 43980117)
135. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90. (Pubitemid 43069209)
136. Colonno R, Rose R, Polkornowski K, Baldick C, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamuvidine refractory patients. Hepatology 2006;44:229A (Abst).
137. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006;13:250-5.
138. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11. (Pubitemid 46355274)
139. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34. (Pubitemid 41376852)
140. Beasley R. Hepatitis B. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
141. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990;150:1051-4. (Pubitemid 20155330)
142. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-66. (Pubitemid 24324044)
143. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7. (Pubitemid 29215551)
144. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437-44.
145. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
146. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5. (Pubitemid 32328514)
147. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10. (Pubitemid 30033708)
148. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000;6:715-20.
149. Kuwahara R, Kumashiro R, Inoue H, et al. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains. Dig Dis Sci 2004;49:300-3. (Pubitemid 38392234)
150. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 Suppl):S6-9. (Pubitemid 43053865)
151. Hall HI, Geduld J, Boulos D, et al. Epidemiology of HIV in the United States and Canada: Current status and ongoing challenges. J Acquir Immune Defic Syndr 2009;(51 Suppl 1):S13-20.
152. Yang Q, Boulos D, Yan P, et al. Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health 2010;101:486-90.
153. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49(5 Suppl):S138-45.
154. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34. (Pubitemid 44306484)
155. Thio C, Seaberg E, Skolasky RJ, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6. (Pubitemid 35472132)
156. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: A cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-71.
157. Lin K, Karwowska S, Lam E, Limoli K, Evans TG, Avila C. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010;54:2670-3.
158. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21. (Pubitemid 46961006)
159. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009;23:546-7.
160. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010;139:1934-41.
161. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006;20:863-70. (Pubitemid 43731568)
162. Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther 2010;15:487-91.
163. Pessoa MG, Gazzard B, Huang AK, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008;22:1779-87.
164. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-8. (Pubitemid 351228130)
165. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-33.
166. Asboe D, Aitken C, Boffito M, et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012;13:1-44.
167. Bellini C, Keiser O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: The Swiss HIV Cohort Study. HIV Med 2009;10:12-8.
168. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5. (Pubitemid 29203534)
169. Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011;25:1013-4.
170. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007;45(Suppl 2):S57-65; discussion S6-7.
171. Rouanet I, Peyriere H, Mauboussin JM, Terrail N, Vincent D. Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis B virus co-infected patient receiving antiretroviral therapy. Eur J Gastroenterol Hepatol 2003;15:95-7. (Pubitemid 36135670)
172. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-7.
173. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010;23:32-8.
174. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003;39:1036-41. (Pubitemid 37523777)
175. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-8. (Pubitemid 47274591)
176. Fattovich G, Tagger A, Brollo L, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis 1991;163:400-2.
177. Crespo J, Lozano JL, de la Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol 1994;89:1147-51. (Pubitemid 24245785)
178. Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991;14:64-7.
179. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: Clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404-6. (Pubitemid 27450186)
180. Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33. (Pubitemid 28122496)
181. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442-8. (Pubitemid 24320846)
182. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54. (Pubitemid 28100034)
183. Lee LP, Dai CY, Chuang WL, et al. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007;22:515-7.
184. Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009;51:446-57.
185. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference. Hepatology 2009;50:46-55.
186. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B/hepatitis C virus-coinfected patients. Hepatology 2006;43:100-7. (Pubitemid 43733596)
187. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and Delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106-10.
188. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009;136:496-504, e3.
189. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009;29:1485-93.
190. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-94.
191. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985;253:1740-5. (Pubitemid 15141106)
192. Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989;1:406-10. (Pubitemid 19059152)
193. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773-81, e2.
194. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: An Australian experience. Med J Aust 2009;190:489-92.
195. Andre FE, Zuckerman AJ. Review: Protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994;44:144-51. (Pubitemid 24324005)
196. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: Protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-30. (Pubitemid 27445742)
197. Singh AE, Plitt SS, Osiowy C, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat 2011;18:468-73.
198. Pan C, Han GR, Zhao W, Xu C, Ge C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants with HBsAg-positive at birth. Hepatology 2011;54(Suppl 4):878A.
199. Han GR, Zhao W, Xu CL, Ge CY, Jiang HX, Pan C. Risk factors associated with perinatal infection of HBV in infants who born to HBsAg and HBeAg positive mothers. Hepatology 2011;54(Suppl 4):444A.
200. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: A multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.
201. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7. (Pubitemid 36801916)
202. Han GR, Jiang H, Zhao W, Ge C, Xu C, Pan C. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission (VT) of chronic hepatitis B (CHB) in highly viremic mothers. Hepatology 2011;54:479A.
203. U.S. Food and Drug Administration Summary of Proposed Rule on Pregnancy and Lactation Labeling. 2008:30831.
204. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011. Wilmington: Registry Coordinating Center; 2011.
205. Viread (Tenofovir DF) Prescribing Information. Gilead Sciences Incorporated. Foster City, CA; Revised January 2012.
206. Tyzeka (Telbivudine) prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey; Revised December 2011.
207. Pol S, Corouge M, Fontaine H. Hepatitis B virus infection and pregnancy. Clin Res Hepatol Gastroenterol 2011;35:618-22.
208. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011;55:1315-7.
209. Gartner LM, Morton J, Lawrence RA, et al. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506.
210. Palda VA, Guise JM, Wathen CN. Interventions to promote breastfeeding: Applying the evidence in clinical practice. CMAJ 2004;170:976-8. (Pubitemid 38392195)
211. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-52. (Pubitemid 34621230)
212. Tseng RY, Lam CW, Tam J. Breastfeeding babies of HBsAg-positive mothers. Lancet 1988;2:1032.
213. de Martino M, Appendino C, Resti M, Rossi ME, Muccioli AT, Vierucci A. Should hepatitis B surface antigen positive mothers breast feed? Arch Dis Child 1985;60:972-4. (Pubitemid 16243965)
214. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002;359:1488-9. (Pubitemid 34457770)
215. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am 2009;35:125-37.
216. Han SH. Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 2004;8:403-18.
217. Kim JD, Sherker AH. Antiviral therapy: Role in the management of extrahepatic diseases. Gastroenterol Clin North Am 2004;33:693-708, xi. (Pubitemid 39485906)
218. Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. Ann Hepatol 2011;10:165-73.
219. Gan SI, Devlin SM, Scott-Douglas NW, Burak KW. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection. Can J Gastroenterol 2005;19:625-9. (Pubitemid 41723288)
220. Ng YY, Yang WC, Lee ST. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy? Kidney Int 2006;69:776.
221. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-8. (Pubitemid 43169919)
222. Shapiro RJ, Steinbrecher UP, Magil A. Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol 1995;15:343-7.
223. Giboa N, Neigut D. Interferon treatment of hepatitis B-associated membranous glomerulonephritis and nephrotic syndrome. Pediatr Nephrol 1993;7:328-9. (Pubitemid 23214002)
224. Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001;344:1645-6. (Pubitemid 32479925)
225. Deleaval P, Stadler P, Descombes E, et al. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: Successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 2001;20:290-2. (Pubitemid 32776479)
226. Mesquita M, Lasser L, Langlet P. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis. Clin Nephrol 2008;70:69-71. (Pubitemid 352005975)
227. Ikee R, Ishioka K, Oka M, et al. Hepatitis B virus-related membranous nephropathy treated with entecavir. Nephrology (Carlton) 2010;15:266.
228. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156-65.
229. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011;31(Suppl 1):104-10.
230. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010;58:254-7.
231. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
232. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004;11:55-9. (Pubitemid 38221618)
233. Bagaglio S, Porrino L, Lazzarin A, Morsica G. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection 2010;38:417-21.
234. Proia LA, Ngui SL, Kaur S, Kessler HA, Trenholme GM. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 2000;108:249-51. (Pubitemid 30100618)
235. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001;32:144-8. (Pubitemid 32150960)
236. Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: Pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2011;9:891-9.
237. Ohishi W, Chayama K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol 2011;15:634-40.
238. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 2012;36:84-93.
239. Arama V, Munteanu D, Olaru I, et al. Reactivation of HBV infection in low grade lymphoma patient. Rom J Intern Med 2011;49:67-73.
240. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9-16.
241. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009;7:1130-7.
242. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616-9. (Pubitemid 28433844)
243. Waite J, Gilson RJ, Weller IV, et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS 1988;2:443-8. (Pubitemid 19040774)
244. Hwang J, Fisch M, Zhang H, et al. Reactivation of hepatitis B infection among patients with cancer. Hepatology 2011;54 (Suppl 4):445A.
245. Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am J Hematol 2005;80:197-203. (Pubitemid 41579541)
246. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-6. (Pubitemid 34761098)
247. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat 2008;15:89-102.
248. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology 2006;43:233-40.
249. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008;47:844-53. (Pubitemid 351449676)
250. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9. (Pubitemid 37500439)
251. Watanabe M, Shibuya A, Takada J, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients. Eur J Intern Med 2010;21:333-7.
252. Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 2010;16:5447-51.
253. Milazzo L, Corbellino M, Foschi A, et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis 2012;14:95-8.
254. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol 2011;55:474-82.
255. Management of healthcare workers infected with hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or other bloodborne pathogens. AIDS/TB Committee of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1997;18:349-63.
256. Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010;31:203-32.
257. Gunson RN, Shouval D, Roggendorf M, et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): Guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003;27:213-30. (Pubitemid 36870896)
258. Niro GA, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep 2012;14:9-14.
259. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007;45:1331-2; author reply 2-3.
260. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: An analysis of clinical studies. Turk J Gastroenterol 2006;17:25-34. (Pubitemid 46534949)
261. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011;12:CD006002.
262. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31.
263. Wong D, Cheung A, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23. (Pubitemid 23319890)